Abstract: METHODS: Thirty-one patients with rtA181T/V mutation and 25 patients with rtA181T/V and rtN236T mutation were enrolled.
Abstract: No significant difference in baseline characteristics was observed between the rt
Method: Among them, 31 patients developed rtA181T/V mutation strains (rtA181 group), and the other 25 patients developed rtA181T/V and rtN236T mutation strains (rtA181 + rtN236 group).
Clinical features and viral quasispecies characteristics associated with infection by the hepatitis B virus G145R immune escape mutant.
Result: We also screened several mutations relevant to antiviral resistance, such as I169L, L180M, A181V, T184I, S202C, M204V/I, N236T and M250I in the RT region.
Analysis of the prevalence of drug-resistant hepatitis B virus in patients with antiviral therapy failure in a Chinese tertiary referral liver centre (2010-2014).
PMID: 28017671
2017
Journal of global antimicrobial resistance
Abstract: M204I, N236T and L180M+M204V+V173L/S202G were the most common substitutions for l-nucleoside (3TC and LdT), ADV and ETV genotypic resistant phenotypes, respectively.
Abstract: N236T incidence in genotype B was significantly higher than in genotype C (43.2% vs.
Comparison of Detection Rate and Mutational Pattern of Drug-Resistant Mutations Between a Large Cohort of Genotype B and Genotype C Hepatitis B Virus-Infected Patients in North China.
PMID: 27792585
2017
Microbial drug resistance (Larchmont, N.Y.)
Abstract: For adefovir-resistant mutations, HBV/C-infected patients had a higher detection rate of rtA181 V (HBV/C 5.29% vs. HBV/B 1.36%, p < 0.01) and a lower detection rate of rtN236T (2.70% vs. 6.54%, p < 0.01).
Prevalence of mutations in HBV DNA polymerase gene associated with nucleos(t)ide resistance in treatment-naive patients with Chronic Hepatitis B in Central China.
PMID: 26876337
2016
The Brazilian journal of infectious diseases
Abstract: Mutations in HBV DNA polymerase were detected in 24 patients (8.9%) including rtM204I/V (n=6), rtN236T (n=5), rtM250V (n=2), rtL180M (n=2), rtT184G (n=1), rtM207I (n=1), rtS202I (n=1), rtM204V/I & rtL180M (n=5), and rtM204I &
Increased occurrence of mutant rtI233V of HBV in patients receiving adefovir therapy.
Abstract: CONCLUSIONS: rtI233V usually emerged in ADV-treated patients with little impact on ADV susceptibility but it effectively restored replication capacity of the rtN236T mutant, suggesting that rtI233V may partly serve as a compensatory mutation associated with ADV resistance.
Abstract: Eight patients with rtI233V +- rtA181V/rtN236T had virological breakthrough in the clinical course of ADV treatment.
Abstract: Phenotypic analysis showed that rtI233V mutants from patient 1 and patient 2
Antiviral efficacy of entecavir versus entecavir plus adefovir for hepatitis B virus rtA181V/T mutants alone.
PMID: 26831605
2016
Saudi journal of gastroenterology
Introduction: In general, the majority of HBV rtA181V/T mutants are known to be induced after ADV therapy, along with the rtN236T mutant.
Dynamics of Genotypic Mutations of the Hepatitis B Virus Associated With Long-Term Entecavir Treatment Determined With Ultradeep Pyrosequencing: A Retrospective Observational Study.
Result: In the PVR group, all treatment-naive patients harbored rtA181 V/T substitutions (ranging from 1.1% to 3.8%) and rtN236T substitutions (ranging from 1.5% to 6.1%).
Discussion: One study reported that the most commonly detected mutations were M204 V/I, M250 V/I, A181T/V, and N236T.
Discussion: UDPS indicated that NAr mutations were pre-existent at low percentages (ranging from 0.1% to 6.7%) at baseline, including rtV173A/M, rtL180 M, rtA181 V/T,
Tenofovir monotherapy versus tenofovir and entecavir combination therapy in adefovir-resistant chronic hepatitis B patients with multiple drug failure: results of a randomised trial.
HBV mutation literature information.
PMID: 
2017
Infection and drug resistance
Browser Board
Co-occurred Entities
Filtrator
ViMRT